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a  b  s  t  r  a  c  t
Aim:  To  characterize  the  population  treated  with  SBRT  for early-stage  primary  lung  tumors  in  our  insti-
tution,  determine  their  outcomes,  and  identify  potential  prognosis  factors.
Background:  Stereotactic  radiotherapy  (SBRT)  is an  alternative  treatment  for  inoperable  patients  with
early-stage  lung  cancer.  It  confers  a local  control  rate  around  90%  at 3 years,  and  2−3  year  overall  survival
rates  of 43–60%  in this  population.
Materials  and  methods:  We  retrospectively  analyzed  all patients  treated  in our department  between  2012
and  2017  and  evaluated  local  progression-free  survival  (L-PFS),  nodal  or distant  progression-free  survival
(ND-PFS),  global  progression-free  survival  (G-PFS),  overall  survival  (OS),  and disease  specific  survival
(DSS).  Univariate  (UVA)  and  multivariate  (MVA)  models  were  built  to assess  the  influence  of each  variable.
Results: We  identified  218  patients  with  233  tumors.  Most  were  male  (78.9%)  with  a  median  age  of
73  years.  Median  follow-up  was  22 months.  At 18 months,  L-PFS  was  93.7%,  ND-PFS  was  82.2%,  G-PFS
was  76.0%,  DSS  was  90.5%,  and  OS  was  78.0%  in  ≤ T2 tumors.  On  UVA,  T2 tumors  were  associated  with
lower  L-PFS,  G-PFS  and  DSS  than T1, with no significant  impact  on  ND-PFS  or OS,  an  effect  that  persisted
on  MVA.  On  UVA,  L-PFS  and  G-PFS  were  negatively  influenced  by female  gender  and  a  5-fraction  schedule
was  associated  with  worse  G-PFS,  which  was  not  confirmed  on  MVA.
Conclusion:  Our local  and  distant  control  rates  and  survival  were  similar  to those  previously  reported.  On
MVA,  T2  tumors  displayed  lower  L-PFS,  G-PFS  and  DSS,  with  no  difference  in  OS.










Lung cancer is the main global cause of death by cancer. Most
are diagnosed in advanced stages. However, around 16% are early-
stage when diagnosed (confined to the thorax with a maximum
diameter less than 5 cm), a number expected to rise as a result of
the implementation of screening programs.1 Surgery remains the
most widely adopted treatment for these early-stage lung cancers.
Many patients are inoperable – most for medical reasons, which can
be understood given the average age at diagnosis of 70 years and the
prevalence of tobacco-related comorbidities in this population.1 In
Abbreviations: L-PFS, local progression-free survival; ND-PFS, nodal or dis-
tant progression-free survival; G-PFS, global progression-free survival; DSS, disease
specific survival; OS, overall survival; UVA, univariate analysis; MVA, multivariate
analysis; AC, Adenocarcinoma; SCC, Squamous Cell Carcinoma.
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1507-1367/© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reshis setting, stereotactic body radiation therapy (SBRT) is the alter-
ative treatment modality, with a reported local control similar to
hat obtained with a surgical approach and low toxicity rates (also
n the elderly population).2,3 As such, it should be offered in inop-
rable patients or those who  refuse surgery.4 SBRT confers a local
ontrol rate of 90% at 3 years, and 2−3 year overall survival rates of
3–60% for medically inoperable patients.5 Its adoption for larger
umors (>5 cm)  has been reported in retrospective studies and, in
pite of conferring an acceptable toxicity profile and disease con-
rol, is associated with lower local and distant control.6 As such,
ur purpose was to retrospectively characterize the population that
as  treated with SBRT for early-stage primary lung tumors in our
epartment, to determine their clinical outcomes, and to identify
he influence of potential prognosis factors.
. MethodsWe retrospectively analyzed all patients treated with SBRT for
rimary early-stage lung tumors in our department between 1st
anuary 2012 and 31st December 2017, and evaluated the influ-
erved.
Reports of Practical Oncology and Radiotherapy 25 (2020) 943–950
Table 1




Median Age (y) (range) 73 years (51−91)
Charlson Comorbidity Score Index (median) (range) 5.5 (1−13)
Number of lesions (n) (%)
1  204 (93.6%)
2  13 (6.0%)
3 1 (0.5%)
ECOG
0  22 (10.1%)
1 132 (60.6%)
2  53 (24.3%)
3 11 (5.0%)
Smoking Status (10 Missing)
Former/Current Smoker 178 (81.7%)
Never Smoker 30 (13.8%)
Table 2
Demographic variables by tumor (n = 233).
Histology (n) (%)
Adenocarcinoma 158 (67.8%)
Squamous Cell Carcinoma 68 (29.2%)
Small-Cell Carcinoma 2 (0.9%)
Non-Small Cell Carcinoma 2 (0.9%)
Carcinoid 1 (0.4%)
Adenosquamous Carcinoma 1 (0.4%)
Large-Cell Neuroendocrine Carcinoma 1 (0.4%)






T2  51 (21.9%)
T2a 36 (15.5%)
T2b 15 (6.4%)
T3  3 (1.3%)
T4 1 (0.4%)
Location
Peripheral (Versus Central) (n) (%) 190 (81.5%)
> 1 cm from Chest Wall (Versus < 1 cm) (n) (%) 116 (49.8%)
ITV (median) (range) 10.5cc (0.2−163.9)
PTV  (median) (range) 31.1cc (4−264.9)
Fractionation (n) (%)
8−10 Gy × 5 fractions 68 (29.2%)
12−12.5  Gy × 4 fractions 89 (38.2%)
18−20  Gy × 3 fractions 22 (9.4%)
30−34  Gy × 1 fraction 54 (23.2%)
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ence of potential prognostic factors related to patient/tumor or
treatment characteristics. Information about age, gender, Charl-
son score, tumor size, location (central vs peripheral; abutting
the thoracic wall or not), histology, number of treated lesions,
treatment technique and fractionation was collected and analyzed.
Patient selection criteria included inoperable patients (due to med-
ical comorbidities or tumor characteristics) or who refused surgery,
without clinical evidence of lymph node spread (cN0). All lesions
were biopsied and patients were staged by computed tomography
(CT) and PET/CT, according to the AJCC 7th edition. Treatment was
planned using free-breathing 4D-CT images and respiratory gating
(with a vacuum cushion, and abdominal compression when appro-
priate). Cone beam CT and fluoroscopy image guidance were used.
Four different fractionation schedules were used, based on RTOG
protocols 0813 (5 alternate-day fractions of 10 Gy),7 0236 (3 frac-
tions of 18–20 Gy)8 and 0915 (1 fraction of 30–34 Gy; 4 fractions
of 12–12.5 Gy)9—all delivering a biologically effective dose (BED)
>100 (100 Gy, 113−180 Gy, 120−150 Gy and 106−113 Gy, respec-
tively, for an / ratio of 10 Gy).
2.1. Response and toxicity evaluation
Treatment response was evaluated by CT scan with contrast,
employing the RECIST criteria,10 every 3 months during the first
two years, every 6 months until the fifth year, and annually there-
after. When there was significant uncertainty in CT evaluations
due to the confounding effect of radiation pneumonitis, cases were
discussed with trained radiologists and, if needed, PET/CT and/or
biopsy were requested. Toxicity was recorded on medical visits
with the same periodicity using the CTCAE scale (v5.0). Treatment
toxicity was considered acute when in the first 6 months after
treatment and late when thereafter.
2.2. Statistical procedures
Data was stored and analyzed using IBM SPSS Statistics Ver-
sion 25. Several clinical outcomes were evaluated. Initial time was
considered as the first day of SBRT and the event day defined as
follows: local progression-free survival (L-PFS, by tumor), until pro-
gression on the treated lesion; nodal or distant progression-free
survival (ND-PFS, by patient), until nodal or distant progression;
global progression-free survival (G-PFS, by patient), until progres-
sion in any location; overall survival (OS, by patient), until death by
any cause; disease specific survival (DSS, by patient), until death
caused by lung cancer. Survival curves were estimated via the
Kaplan-Meier estimator and the Log-Rank test was used to com-
pare survival between groups. Hazard ratios were calculated using
Cox proportional hazards regression models. First, univariate mod-
els were built to determine individual contribution of each of the
following variables: gender, Eastern Cooperative Oncology Group
Performance Status (ECOG), histology, tumor stage, smoking sta-
tus (former/current smoker or never smoker), number of treated
lesions, location within the lung (centrality; proximity to chest
wall), fractionation and SBRT technique. In a second stage, mul-
tivariable models retaining only the significant variables (p value <
0.05) were built.
3. Results
SBRT was performed in 218 patients with 233 tumors in the
analyzed period. Most were males (78.9%) with a median age of
73 years (from 51 to 91 years) and a median Charlson score of
5.5 (from 1 to 13). Most patients had an ECOG of 0 or 1 (70.7%)
and had a history of tobacco exposure (81.7%). Median follow-up
time was 22 months (from 0 to 67 months). Information regard-






xcluded from outcome analysis. Most patients had one lesion
ndergoing SBRT (93.6%) – 13 patients had two and 1 had three.
he majority of tumors were adenocarcinomas (67.8%), followed
y squamous cell carcinomas (29.2%). The majority of lesions were
eripheral (81.5%) and about half were located > 1 cm from the
hest wall (49.8%). Median maximum diameter was 2.3 cm,  varying
rom 0.5 to 7.5 cm – 76.4% were T1(a, b or c) and 21.9% were T2(a
r b). Median internal target volume (ITV) was  10.5cc (from 0.2
o 163.9cc) and median planning target volume (PTV) was 31.1cc
from 4 to 264.9cc). Three-dimensional conformal radiation ther-
py (3DCRT) was the most frequently used planning technique (in
3.1%), followed by VMAT (in 22.3%) and IMRT (in 14.6%). The four-
raction schedule was  used on 38.2% of tumors, the five-fraction
n 29.2%, the one-fraction on 23.2% and the three-fraction on 9.4%
Tables 1 and 2].
The most frequently observed acute toxicities were grade I
neumonitis (in 22.0%), grade I cough (in 6%) and grade I asthenia.







G1  13 (6%)












G2  6 (2.8%)
Dyspnea
G1 14 (6.4%)




G2  2 (0.9%)
Cough
G1 13 (6%)



























































Rib Fracture 5 (2.2%)
Dermatitis
G1 3 (1.4%)
No grade ≥ III acute toxicities were noted. In a late setting, the most
common was grade I pneumonitis (39.9%), grade I chest wall pain
(6.4%) and grade I dyspnea (6.4%). Five rib fractures were identi-
fied in follow-up imaging evaluation. The only grade III late toxicity
registered was dyspnea in 1 patient [Table 3].
At follow-up, a complete local response was obtained in 19% of
lesions, a partial response in 22%, and stable disease in 46%. Disease
progression was observed in the treated site in 11.5% patients, else-
where in the lung in 8.4%, in hilar or mediastinal nodes in 10.7% and
a distant progression was verified in 12.1%. In ≤ T2 tumors, respec-
tively at 18 and 24 months, L-PFS was 93.7% and 89.2%, ND-PFS
was 82.2% and 78.2%, G-PFS was 76.0% and 68.5%, DSS was 90.5%
and 84.4%, and OS was 78.0% and 67.6%.
On univariate analysis, when analyzing T1 versus T2 lesions,
a higher tumor stage was significantly associated with lower 18-
month L-PFS (95.3% for T1 vs. 90.4% for T2, with a p value of 0.029),
G-PFS (80.2% for T1 vs. 65.3% for T2, p < 0.001) and DSS (92.3% for
T1 vs. 86.2% for T2, p = 0.009). However, it had no significant impact
on OS (p = 0.302) or ND-PFS (p = 0.085), with a trend towards worse
prognosis in T2 tumors [Fig. 1]. On a multivariate analysis model
including tumor stage (T1 vs. T2), gender, fractionation schedule
and location within the lung (central vs. peripheral), a T2 tumor
stage was the only predictor of worse L-PFS (HR 2.524, p = 0.037),
G-PFS (HR 2.371, p = 0.001) and DSS (HR 2.348, p = 0.016). OS and
ND-PFS were not influenced by any variable in multivariate analy-
sis.
Three T3 and one T4 tumors underwent SBRT (staged as such due
to tumor size), with a median maximum diameter of 6.25 cm (from
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ost-treatment, two  died after relapse (7 and 19 months after SBRT
 one relapsed on the treated lesion and hilar/mediastinal lymph
odes, and the other developed other lesions on the same lobe), and
ne died 5 months after SBRT with no evidence of disease relapse
with partial response on the treated lesion). Since they were a
inority, they were not included in the Kaplan-Meier model for
ize comparison.
On univariate analysis, female gender seemed to have a negative
nfluence on L-PFS and G-PFS (p = 0.048 and p = 0.044, respectively),
ith no influence on ND-PFS, DSS and OS (p = 0.222, p = 0.564 and
 = 0.205). However, this effect did not translate into multivariate
nalysis.
Fractionation also did not influence outcome, both in univari-
te and multivariate analysis when analyzing for L-PFS, ND-PFS,
SS and OS (p > 0.05). We  did observe a statistically significant dif-
erence for G-PFS in univariate analysis, with worse outcomes for
atients undergoing the 5-fraction schedule (80.3% for 1-fraction,
0.7% for 3-fraction, 75.3% for 4 fraction and 70.9% for 5-fraction
chedules; p = 0.008), but that finding was  not observed in multi-
ariate analysis.
Location within the lung also influences the choice of fraction-
tion (along with tumor size) and was, therefore, included in the
ultivariate model. It did not seem to independently influence any
f the outcomes. We  also did not observe any significant effect of
istology (when comparing adenocarcinoma with squamous cell
arcinoma), ECOG, smoking history, SBRT technique or number of
reated lesions for any of the outcomes [Table 4].
. Discussion
The aim of this study was to determine the outcome of patients
ith early-stage lung cancer treated with SBRT in our Institution,
nd to evaluate the influence of several factors on prognosis. Our
rogression-free survival, disease-specific survival and overall sur-
ival rates are in line with literature reported outcomes.11 A review
y Tandberg et al. described 3-year local control rates of around 90%
n most studies.5 A study by Hörner-Rieber et al. also reported 2-
ear local control rates of 90%, distant control of 79% and overall
urvival of 68%, which are in line with those of our series.12 Simi-
arly, Giuliani et al. reported 2-year DSS of 89.9% and OS of 63.7%,
oth aligning with our findings.3
Tumor size has been previously studied as a prognosis factor in
ung SBRT. By comparing T1 and T2 tumors, Dunlap et al. observed
hat T2 tumors had significantly lower local control rates and a
horter mean time to local recurrence, and trended towards lower
verall survival rates.13 Baumann et al. also compared T1 with T2
umors and concluded that patients with T2 tumors had a signifi-
antly higher risk of failure in any location (local, nodal or distant).
owever, there was no difference in overall survival, progression-
ree survival or disease-specific survival. Several other studies have
lso concluded that larger GTVs are associated with more frequent
ocal recurrences.2,14 Nevertheless, this association between tumor
ize and outcome after lung SBRT is not consensual. Allibhai et al.
ound that tumor size did not relate to local failure, but only to
egional and distant failure, as well as overall and disease-free
urvival.15 In the other hand, Marhawa et al. did not observe any
ignificant differences when comparing nodal failure rates between
atients with different sized primary tumors (except when com-
aring cT1a with cT1b tumors).16
The absence of association between T-stage and OS possibly
elates to population characteristics. Since most patients undergo
BRT for lack of clinical eligibility criteria for surgery, it can be
nderstood that their comorbid conditions could also play an
mportant role in limiting their life expectancy. In fact, in a Dutch
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Table  4
Univariate (UVA) and Multivariate (MVA) Analysis for each outcome. L-PFS: local progression-free survival; ND-PFS: nodal or distant progression-free survival; G-PFS: global
progression-free survival; DSS: disease-specific survival; OS: overall survival AC: Adenocarcinoma; SCC: Squamous Cell Carcinoma.
L-PFS
UVA MVA
HR [95% CI] p-value HR [95% CI] p-value
T Stage
(T1 vs T2) 2.536 [1.065−6.039] 0.029 2.524 [1.059−6.015] 0.037
Gender
(Male  vs Female) 2.533 [1.119−5.734] 0.021 0.079
Fractionation Schedule
1 fraction 1
3 fractions 0.367 [0.040−3.343] 0.209 0.622
4  fractions 1.078 [0.325−3.575]
5  fractions 2.038 [0.638−6.509]
Location Within the Lung
(Peripheral vs Central) 1.638 [0.650−4.130] 0.291 0.650
Histology
(AC  vs SCC) 0.865 [0.343−2.185] 0.759 –
Technique
3DRT  (Reference) 1
IMRT 0.598 [0.136−2.632] 0.782 –
VMAT 0.870 [0.256−2.963]
Smoking Status
(Non-smoker vs Smoker) 0.541 [0.212−1.379] 0.191 –
ECOG
0  (Reference) 1
1 1.535 [0.351−6.719] 0.854 –
2  1.442 [0.279−7.454]
3  2.380 [0.333−17.006]
Number of treated lesions
(1 vs 2) 1.115 [0.331−3.754] 0.861 –
ND-PFS
UVA MVA
HR [95% CI] p-value HR [95% CI] p-value
T Stage
(T1 vs T2) 1.761 [0.917−3.384] 0.085 0.093
Gender
(Male  vs Female) 1.607 [0.852−3.032] 0.139 0.223
Fractionation Schedule
1 fraction 1
3  fractions 0.591 [0.119−2.935] 0.081 0.115
4  fractions 1.842 [0.735−4.615]
5  fractions 2.455 [0.967−6.236]
Location Within the Lung
(Peripheral vs Central) 1.836 [0.944−3.569] 0.069 0.131
Histology
(AC  vs SCC) 0.604 [0.289−1.260] 0.174 –
Technique
3DRT  (Reference) 1
IMRT 1.211 [0.549−2.716] 0.873 –
VMAT 0.962 [0.400−2.313]
Smoking Status
(Non-smoker vs Smoker) 1.608 [0.574−4.503] 0.362 –
ECOG
0  (Reference) 1
1  2.600 [0.615−10.990] 0.183 –
2  4.013 [0.903−17.841]
3  4.237 [0.775−23-152]
Number of treated lesions
(1 vs 2) 1.363 [0.487−3.810] 0.554 –
G-PFS
UVA MVA
HR [95% CI] p-value HR [95% CI] p-value
T Stage
(T1 vs T2) 2.421 [1.454−4.029] <0.001 2.371 [1.425−3.947] 0.001
Gender
(Male  vs Female) 1.730 [1.041−2.875] 0.041 0.075
Fractionation Schedule
1 fraction 1
3 fractions 0.412 [0.114−1.487] 0.008 0.191
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Table  4 (Continued)
L-PFS
UVA MVA
HR [95% CI] p-value HR [95% CI] p-value
4 fractions 1.336 [0.661−2.698]
5  fractions 2.176 [1.077−4.395]
Location Within the Lung
(Peripheral vs Central) 1.839 [1.073−3.153] 0.024 0.113
Histology
(AC  vs SCC) 0.761 [0.439−1.319] 0.329 –
Technique
3DRT  (Reference) 1
IMRT 1.123 [0.556−2.270] 0.228 –
VMAT 1.714 [0.921−3.192]
Smoking Status
(Non-smoker vs Smoker) 0.854 [0.436−1.673] 0.645 –
ECOG
0  (Reference) 1
1 1.719 [0.678−4.356] 0.346 –
2  2.326 [0.861−6.288]
3  2.258 [0.651−7.830]
Number of treated lesions
(1 vs 2) 1.570 [0.718−3.434] 0.255 –
DSS
UVA MVA
HR [95% CI] p-value HR [95% CI] p-value
T Stage
(T1 vs T2) 2.464 [1.225−4.658] 0.009 2.348 [1.175−4.691] 0.013
Gender
(Male  vs Female) 1.343 [0.646−2.791] 0.428 0.583
Fractionation Schedule
1 fraction 1
3  fractions 0.590 [0.113−3.089] 0.117 0.588
4  fractions 1.408 [0.501−3.956]
5  fractions 2.355 [0.855−6.490]
Location Within the Lung
(Peripheral vs Central) 1.505 [0.707−3.203] 0.285 0.670
Histology
(AC  vs SCC) 1.086 [0.531−2.220] 0.821 –
Technique
3DRT  (Reference) 1
IMRT 1.376 [0.550−3.444] 0.694 –
VMAT 0.808 [0.281−2.326]
Smoking Status
(Non-Smoker vs Smoker) 1.050 [0.408−2.702] 0.920 –
ECOG
0  (Reference) 1
1  1.730 [0.520−5.758] 0.813 –
2  1.396 [0.359−5.421]
3  1.491 [0.248−8.967]
Number of treated lesions
(1 vs 2) 2.079 [0.807−5.351] 0.121 –
OS
UVA MVA
HR [95% CI] p-value HR [95% CI] p-value
T Stage
(T1 vs T2) 1.315 [0.780−2.218] 0.303 0.346
Gender
(Male  vs Female) 0.699 [0.386−1.267] 0.236 0.264
Fractionation Schedule
1 fraction 1
3 fractions 0.474 [0.187−1.203] 0.192 0.325
4  fractions 0.726 [0.403−1.306]
5  fractions 1.094 [0.613−1.952]
Location Within the Lung
(Peripheral vs Central) 1.113 [0.642−1.930] 0.703 1.000
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Table  4 (Continued)
L-PFS
UVA MVA
HR [95% CI] p-value HR [95% CI] p-value
Histology
(AC vs SCC) 1.164 [0.727−1.863] 0.526 –
Technique
3DRT  (Reference) 1
IMRT 1.102 [0.581−2.092] 0.852 –
VMAT 1.178 [0.641−2.163]
Smoking Status
(Non-Smoker vs Smoker) 0.998 [0.527−1.890] 0.994 –
ECOG
0  (Reference) 1
1 2.152 [0.853−5.431] 0.114 –
2  2.744 [1.032−7.294]
3  0.929 [0.179−4.822]
Number of treated lesions
(1 vs 2) 1.280 [0.589−2.782] 0.532 –





































study it was found that more than two-thirds of deaths in a lung
cancer cohort occurred due to unrelated causes.17
We  observed a gender difference in L-PFS and G-PFS with
a significant trend towards inferior outcome on females, only
in univariate analysis. In our series, this does not translate into
multivariate analysis, probably owing to the influence of other vari-
ables. In opposition, in a study by Pham et al., female gender was
associated with more favourable OS in univariate analysis, with
borderline significance in multivariate analysis (p = 0.0535).18 The
SPACE trial also reported a trend towards better OS in females
(p = 0.13),11 which was also described by Jeppesen et al. and statis-
tically significant in their retrospective series.19 It became known
from screening studies that women have a higher incidence of lung
cancer than men  (almost double after adjusting for smoking history
and age). However, they have shown to have a lower hazard ratio
of fatal outcome (HR 0.48, 95% CI 0.25−0.89).20 These findings are
not corroborated by our data.
Our in-house protocol for lung SBRT encompasses four different
treatment schedules based on three RTOG protocols,7–9 selected
on a case-by-case basis according to tumor size and location.
One-fraction schedules are preferred for small peripheral lesions
located away from the chest wall (>1 cm). Three or four-fraction
schedules are used for larger lesions or those close to the chest
wall, respectively. Central tumors, when eligible for SBRT, undergo
five-fraction schedules, according to tolerance doses to organs at
risk determined during planning. Recent ACROP-ESTRO guidelines
suggested different fractionation schedules, not including the one-
fraction schedule.21 However, according to our results, and with
appropriate patient selection and image verification procedures,
no fractionation schedule entails inferior survival outcomes. The
low number and severity of side effects in our cohort also did not
allow us to infer any influence of fractionation. Therefore, when
appropriately performed, one-fraction schedules do not seem to be
inferior to multiple-fraction schedules. This has also been reported
in prospective studies, such as RTOG 0915 and I-124407, which did
not identify any significant increase in toxicity or decrease in tumor
control rates or survival when comparing one-fraction schedules
with three or four-fraction schedules.9,22 We  did, however, observe
a difference in G-PFS in univariate analysis, with a lower progno-
sis after 5-fraction schedules. These patients have typically larger
lesions, which could account for this difference, especially since
this was not a significant variable in multivariate analysis. The BED




948hat of other schedules in our protocol, which could also contribute
o this difference.
Although histology has previously been described as a prognosis
actor, we  observed no difference in outcome between adenocar-
inomas and squamous cell carcinomas in our population, both
n univariate and multivariate analysis. On the first retrospective
tudy demonstrating an eventual effect of histology on outcome,
oody et al. found that a squamous histology was a strong pre-
ictor of local failure (with a twofold higher incidence of local
elapse).23 Another unicentric study with similar findings deter-
ined that this effect was  not evident when EQD2 (2 Gy equivalent
ose) was ≥150 Gy.12 Although other studies did not observe this
nfluence, a multi-institutional analysis also noted more frequent
ocal, regional and distant failures, a shorter median time to recur-
ence and a higher risk for death in squamous cell tumors when
ompared to adenocarcinomas after SBRT.24 We  did not observe a
ignificant difference in outcome between the two, and therefore
annot corroborate the possibility that squamous cell carcinomas
ay  be more radioresistant to SBRT than adenocarcinomas.
Other predictors of worse prognosis reported in the litera-
ure are higher maximum SUV (standard uptake value) on PET
valuation,25,26 age27 and cardiac dose.28 These were not analyzed
n our study.
In our population, the dominant patterns of recurrence were dis-
ant and nodal spread. This finding aligns with literature-reported
atterns, with reported distant recurrence rates of around 20% at
–4 years and regional recurrences in about 10% patients.3 Verma
t al. also observed distant recurrence in 21% patients (with tumors
arger than 5 cm), accounting for 33% disease recurrences, the main
attern of recurrence in this series.6 Adjuvant systemic therapies,
specially with well tolerated drugs (given the comorbid burden
f the population that is usually treated with SBRT) could have a
ole in improving disease-specific survival and decreasing nodal
nd distant relapse, especially in larger tumors.
This study has some limitations. Its retrospective nature could
ventually imply some missing data, in case they were not regis-
ered in the clinical records for appropriate collection. On the other
and, the low number of cases with G2−3 toxicity did not allow any
orrelation between significant toxicity and patient or treatment
haracteristics. Also, this is a heterogeneous patient population,
ypically with several comorbidities that could shorten their life
xpectancy (and therefore decrease the follow-up time for disease
rogression evaluation).
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mittee.progression-free survival; DSS: disease-specific survival; OS: overall survival.
5. Conclusion
In our series, we observed local and distant control rates and sur-
vival similar to those reported in the literature. T2 tumors displayed
lower L-PFS, G-PFS and DSS rates when compared to T1 tumors,
both in univariate and multivariate analysis. They did not, how-
ever, show any difference in OS in multivariate analysis, which can
be understood given the characteristics of the population treated
with SBRT, typically older and more fragile. Other potential factors
tested (namely gender, ECOG, smoking history, histology, number
of treated lesions, location within the lung, fractionation schedule
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